A citation-based method for searching scientific literature

Leo Meriranta, Annika Pasanen, Amjad Alkodsi, Jari Haukka, Marja-Liisa Karjalainen-Lindsberg, Sirpa Leppä. Blood Adv 2020
Times Cited: 12







List of co-cited articles
93 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
754
66

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
66

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
881
58

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
561
50

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Andrew Davies, Thomas E Cummin, Sharon Barrans, Tom Maishman, Christoph Mamot, Urban Novak, Josh Caddy, Louise Stanton, Shamim Kazmi-Stokes, Andrew McMillan,[...]. Lancet Oncol 2019
112
50


Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
41

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
Nathalie A Johnson, Kerry J Savage, Olga Ludkovski, Susana Ben-Neriah, Ryan Woods, Christian Steidl, Martin J S Dyer, Reiner Siebert, John Kuruvilla, Richard Klasa,[...]. Blood 2009
429
41

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Andreas Rosenwald, George Wright, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Randy D Gascoyne, H Konrad Muller-Hermelink, Erlend B Smeland, Jena M Giltnane,[...]. N Engl J Med 2002
41

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Zijun Y Xu-Monette, Lin Wu, Carlo Visco, Yu Chuan Tai, Alexander Tzankov, Wei-min Liu, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, Attilio Orazi,[...]. Blood 2012
232
33

Stromal gene signatures in large-B-cell lymphomas.
G Lenz, G Wright, S S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal,[...]. N Engl J Med 2008
33

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.
Nikita Kotlov, Alexander Bagaev, Maria V Revuelta, Jude M Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina,[...]. Cancer Discov 2021
49
33

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
George W Wright, Da Wei Huang, James D Phelan, Zana A Coulibaly, Sandrine Roulland, Ryan M Young, James Q Wang, Roland Schmitz, Ryan D Morin, Jeffrey Tang,[...]. Cancer Cell 2020
270
33

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
Annette M Staiger, Michael Altenbuchinger, Marita Ziepert, Christian Kohler, Heike Horn, Michael Huttner, Katrin S Hüttl, Gunther Glehr, Wolfram Klapper, Monika Szczepanowski,[...]. Leukemia 2020
18
33

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh,[...]. J Clin Oncol 2019
226
33

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Daisuke Ennishi, Aixiang Jiang, Merrill Boyle, Brett Collinge, Bruno M Grande, Susana Ben-Neriah, Christopher Rushton, Jeffrey Tang, Nicole Thomas, Graham W Slack,[...]. J Clin Oncol 2019
153
33

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
Stuart E Lacy, Sharon L Barrans, Philip A Beer, Daniel Painter, Alexandra G Smith, Eve Roman, Susanna L Cooke, Camilo Ruiz, Paul Glover, Suzan J L Van Hoppe,[...]. Blood 2020
129
33

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
482
33

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
661
33

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Kerry J Savage, Graham W Slack, Anja Mottok, Laurie H Sehn, Diego Villa, Roopesh Kansara, Robert Kridel, Christian Steidl, Daisuke Ennishi, King L Tan,[...]. Blood 2016
113
33

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.
Matias Autio, Suvi-Katri Leivonen, Oscar Brück, Satu Mustjoki, Judit Mészáros Jørgensen, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Harald Holte, Teijo Pellinen, Sirpa Leppä. Haematologica 2021
39
33

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
33

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Sharon Barrans, Simon Crouch, Alex Smith, Kathryn Turner, Roger Owen, Russell Patmore, Eve Roman, Andrew Jack. J Clin Oncol 2010
418
25

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Briere, Richard Delarue, Danielle Canioni, Gilles Salles, Marie Parrens, Karim Belhadj, Bettina Fabiani,[...]. Blood 2015
155
25

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Qing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, Lijuan Deng, Xiaoxiao Wang, Ganiraju C Manyam, Carlo Visco, Santiago Montes-Moreno, Li Zhang, Karen Dybkær,[...]. Oncotarget 2016
70
25

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
Yasuhiro Oki, Mansoor Noorani, Pei Lin, Richard E Davis, Sattva S Neelapu, Long Ma, Mohamed Ahmed, Maria Alma Rodriguez, Fredrick B Hagemeister, Nathan Fowler,[...]. Br J Haematol 2014
248
25

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.
Daisuke Ennishi, Anja Mottok, Susana Ben-Neriah, Hennady P Shulha, Pedro Farinha, Fong Chun Chan, Barbara Meissner, Merrill Boyle, Christoffer Hother, Robert Kridel,[...]. Blood 2017
89
25

MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Shaoying Li, Parth Desai, Pei Lin, C Cameron Yin, Guilin Tang, Xuan J Wang, Sergej N Konoplev, Joseph D Khoury, Carlos E Bueso-Ramos, L Jeffrey Medeiros. Histopathology 2016
58
25


MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Heike Horn, Marita Ziepert, Claudia Becher, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Michael Hummel, Harald Stein, Martin-Leo Hansmann,[...]. Blood 2013
386
25

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy,[...]. J Clin Oncol 2019
181
25

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
David W Scott, Rebecca L King, Annette M Staiger, Susana Ben-Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W Slack, Daisuke Ennishi,[...]. Blood 2018
109
25

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
Andreas Rosenwald, Susanne Bens, Ranjana Advani, Sharon Barrans, Christiane Copie-Bergman, Mad-Helenie Elsensohn, Yaso Natkunam, Maria Calaminici, Birgitta Sander, Maryse Baia,[...]. J Clin Oncol 2019
94
25

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Levi D Pederson, Mei-Yin C Polley, Brandelyn N Pitcher, Bruce D Cheson, Brad S Kahl,[...]. J Clin Oncol 2019
175
25

Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
Madhavi Challa-Malladi, Yen K Lieu, Olivia Califano, Antony B Holmes, Govind Bhagat, Vundavalli V Murty, David Dominguez-Sola, Laura Pasqualucci, Riccardo Dalla-Favera. Cancer Cell 2011
293
25

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Ziju Y Xu-Monette, Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, Raul Torres-Ruiz, Ganiraju C Manyam, Carlo Visco,[...]. Cancer Immunol Res 2019
62
25

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel,[...]. J Clin Oncol 2017
139
25

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
713
16

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.
Izidore S Lossos, Debra K Czerwinski, Ash A Alizadeh, Mark A Wechser, Rob Tibshirani, David Botstein, Ronald Levy. N Engl J Med 2004
694
16

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Laurie H Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J Savage, Tamara Shenkier, Judy Sutherland,[...]. Blood 2007
928
16

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Kerry J Savage, Nathalie A Johnson, Susana Ben-Neriah, Joseph M Connors, Laurie H Sehn, Pedro Farinha, Douglas E Horsman, Randy D Gascoyne. Blood 2009
463
16

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Georg Lenz, Eliza Hawkes, Gregor Verhoef, Corinne Haioun, Soon Thye Lim, Dae Seog Heo, Kirit Ardeshna, Geoffrey Chong, Jacob Haaber, Wei Shi,[...]. Leukemia 2020
29
16

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
William W L Choi, Dennis D Weisenburger, Timothy C Greiner, Miguel A Piris, Alison H Banham, Jan Delabie, Rita M Braziel, Huimin Geng, Javeed Iqbal, Georg Lenz,[...]. Clin Cancer Res 2009
470
16

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
Ken H Young, Karen Leroy, Michael B Møller, Gisele W B Colleoni, Margarita Sánchez-Beato, Fábio R Kerbauy, Corinne Haioun, Jens C Eickhoff, Allen H Young, Philippe Gaulard,[...]. Blood 2008
131
16

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.
Amjad Alkodsi, Alejandra Cervera, Kaiyang Zhang, Riku Louhimo, Leo Meriranta, Annika Pasanen, Suvi-Katri Leivonen, Harald Holte, Sirpa Leppä, Rainer Lehtonen,[...]. Leukemia 2019
14
16

Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
Davide Rossi, Fary Diop, Elisa Spaccarotella, Sara Monti, Manuela Zanni, Silvia Rasi, Clara Deambrogi, Valeria Spina, Alessio Bruscaggin, Chiara Favini,[...]. Blood 2017
134
16

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Zijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, Xin Cao, Alexandar Tzankov, Carol Visco, Lalitha Nagarajan, Qingqing Cai, Santiago Montes-Moreno, Yuji An,[...]. Oncotarget 2015
53
16

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
Laura K Hilton, Jeffrey Tang, Susana Ben-Neriah, Miguel Alcaide, Aixiang Jiang, Bruno M Grande, Christopher K Rushton, Merrill Boyle, Barbara Meissner, David W Scott,[...]. Blood 2019
45
16

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
David W Scott, Anja Mottok, Daisuke Ennishi, George W Wright, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S Barry, Christoffer Hother, Pau Abrisqueta,[...]. J Clin Oncol 2015
239
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.